Published in Healthcare Mergers, Acquisitions and Ventures Week, January 20th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Cytokinetics.
Report 1: Cytokinetics, Incorporated (CYTK) reported revenues from research and development collaborations of $0.1 million for the third quarter of 2006.
Net loss for the third quarter of 2006 was $14.9 million, or $0.41 per share. As of September 30, 2006, cash, cash equivalents, restricted cash and marketable securities totaled $93.9 million.
"The third quarter of 2006 was exciting for Cytokinetics as we presented promising data from our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.